Share this article on:

Transmitted drug resistance in French HIV-2-infected patients

Charpentier, Charlottea; Visseaux, Benoita; Bénard, Antoineb; Peytavin, Gillesc; Damond, Florencea; Roy, Célineb; Taieb, Audreyb; Chêne, Genevièveb; Matheron, Sophied; Brun-Vézinet, Françoisea; Descamps, Dianea; the ANRS CO5 HIV-2 Cohort

doi: 10.1097/QAD.0b013e32836207f3
Research Letters

We report the first transmitted drug resistance survey study in HIV-2-infected patients living in France. The prevalence of transmitted drug resistance was 5.0% (95% confidence interval, 0.1–9.9) with mutations detected only in protease, not in reverse transcriptase. In this series, 10% of patients displayed X4/dual-mixed viruses. These findings classified the rate of transmitted drug resistance in the HIV-2 French Cohort as low prevalence.

aLaboratoire de Virologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Bichat-Claude Bernard, HUPNVS, Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris

bINSERM U897, ISPED, Bordeaux Segalen University, Bordeaux

cLaboratoire de Pharmacologie

dService des Maladies Infectieuses et Tropicales, AP-HP, Groupe Hospitalier Bichat-Claude Bernard, HUPNVS, Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, Paris, France.

Correspondence to Dr Charlotte Charpentier, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, 46 Rue Henri Huchard, 75018 Paris, France. Tel: +33 1 40 25 61 50; fax: +33 1 40 25 67 69; e-mail: charlotte.charpentier@bch.aphp.fr

Received 13 February, 2013

Revised 4 April, 2013

Accepted 5 April, 2013

© 2013 Lippincott Williams & Wilkins, Inc.